Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis

Pirfenidone is an anti-fibrotic drug which has been approved for the management of patients with Idiopathic Pulmonary Fibrosis (IPF). However, its role in interstitial lung disease (ILD) due to other causes such as systemic sclerosis (SSc) is not clear. We present a case of a patient with SSc associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Udwadia, Zarir F., Mullerpattan, Jai B., Balakrishnan, Canchi, Richeldi, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298919/
https://www.ncbi.nlm.nih.gov/pubmed/25624597
http://dx.doi.org/10.4103/0970-2113.148451
_version_ 1782353323069800448
author Udwadia, Zarir F.
Mullerpattan, Jai B.
Balakrishnan, Canchi
Richeldi, Luca
author_facet Udwadia, Zarir F.
Mullerpattan, Jai B.
Balakrishnan, Canchi
Richeldi, Luca
author_sort Udwadia, Zarir F.
collection PubMed
description Pirfenidone is an anti-fibrotic drug which has been approved for the management of patients with Idiopathic Pulmonary Fibrosis (IPF). However, its role in interstitial lung disease (ILD) due to other causes such as systemic sclerosis (SSc) is not clear. We present a case of a patient with SSc associated ILD who showed a subjective as well as objective improvement in lung function with pirfenidone.
format Online
Article
Text
id pubmed-4298919
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-42989192015-01-26 Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis Udwadia, Zarir F. Mullerpattan, Jai B. Balakrishnan, Canchi Richeldi, Luca Lung India Case Report Pirfenidone is an anti-fibrotic drug which has been approved for the management of patients with Idiopathic Pulmonary Fibrosis (IPF). However, its role in interstitial lung disease (ILD) due to other causes such as systemic sclerosis (SSc) is not clear. We present a case of a patient with SSc associated ILD who showed a subjective as well as objective improvement in lung function with pirfenidone. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4298919/ /pubmed/25624597 http://dx.doi.org/10.4103/0970-2113.148451 Text en Copyright: © Lung India http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Udwadia, Zarir F.
Mullerpattan, Jai B.
Balakrishnan, Canchi
Richeldi, Luca
Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
title Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
title_full Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
title_fullStr Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
title_full_unstemmed Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
title_short Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
title_sort improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298919/
https://www.ncbi.nlm.nih.gov/pubmed/25624597
http://dx.doi.org/10.4103/0970-2113.148451
work_keys_str_mv AT udwadiazarirf improvedpulmonaryfunctionfollowingpirfenidonetreatmentinapatientwithprogressiveinterstitiallungdiseaseassociatedwithsystemicsclerosis
AT mullerpattanjaib improvedpulmonaryfunctionfollowingpirfenidonetreatmentinapatientwithprogressiveinterstitiallungdiseaseassociatedwithsystemicsclerosis
AT balakrishnancanchi improvedpulmonaryfunctionfollowingpirfenidonetreatmentinapatientwithprogressiveinterstitiallungdiseaseassociatedwithsystemicsclerosis
AT richeldiluca improvedpulmonaryfunctionfollowingpirfenidonetreatmentinapatientwithprogressiveinterstitiallungdiseaseassociatedwithsystemicsclerosis

Ejemplares similares